HS-20118 vs icotrokinra
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Psoriasis
Shared mechanism: IL-23 receptor · full Psoriasis pipeline
HS-20118
Developed by Avere Therapeutics under a licence from Hansoh Pharmaceutical Group
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: February 2027 · NCT07765628 (registry estimate)
No aligned efficacy figure on record for this race.
icotrokinra · Icotyde
Marketed by Johnson & Johnson and partners
NCT06095115 · Phase 3 · active, not recruiting
Participants were randomly assigned 2:1 to the drug or placebo, with participants and investigators masked, and 684 people enrolled. Both co-primary endpoints, an IGA score of 0 or 1 with at least a 2-grade improvement and PASI 90 at Week 16, are validated clinical measures of skin disease, and both were met with high statistical significance (p<0.001).
Reported efficacy
Percentage of Participants Who Achieved an Investigator's Global Assessment (IGA) Score of 0 or 1 and Greater Than or Equal to (>=) 2-Grade Improvement From Baseline at Week 16; Percentage of Participants Who Achieved Psoriasis Area and Severity Index (PASI) 90 Response at Week 16: Percentage of Participants Who Achieved an Investigator's Global Assessment (IGA) Score of 0 or 1 and Greater Than or Equal to (>=) 2-Grade Improvement From Baseline at Week 16 (Week 16): JNJ-77242113 200 mg 64.7% (met)
Result source: NCT06095115
Results for Psoriasis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | HS-20118 | icotrokinra |
|---|---|---|
| PASI 75 | —Not reported | 65.1% vs 9.3%+55.8 vs placeboNCT052238686 other results
|
| PASI 90 | —Not reported | 46.5% vs 2.3%+44.2 vs placeboNCT052238686 other results
|
| PASI 100 | —Not reported | 23.3% vs 0%+23.3 vs placeboNCT052238686 other results
|
| sPGA 0/1 | —Not reported | —Trial running · NCT06295692 |
| DLQI, change | —Not reported | —Trial running · NCT06295692 |
PASI 75
- HS-20118
- —Not reported
- icotrokinra
- 65.1% vs 9.3%+55.8 vs placeboNCT05223868
6 other results
- 78.6% vs 9.3% NCT05223868
- 58.1% vs 9.3% NCT05223868
- 73.5% vs 4.2% NCT05357755
- 37.2% vs 9.3% NCT05223868
- 51.2% vs 9.3% NCT05223868
- 41.9% vs 4.2% NCT05357755
PASI 90
- HS-20118
- —Not reported
- icotrokinra
- 46.5% vs 2.3%+44.2 vs placeboNCT05223868
6 other results
- 59.5% vs 2.3% NCT05223868
- 51.2% vs 2.3% NCT05223868
- 52.9% vs 0% NCT05357755
- 25.6% vs 2.3% NCT05223868
- 26.8% vs 2.3% NCT05223868
- 25.8% vs 0% NCT05357755
PASI 100
- HS-20118
- —Not reported
- icotrokinra
- 23.3% vs 0%+23.3 vs placeboNCT05223868
6 other results
- 40.5% vs 0% NCT05223868
- 25.6% vs 0% NCT05223868
- 23.5% vs 0% NCT05357755
- 11.6% vs 0% NCT05223868
- 9.8% vs 0% NCT05223868
- 9.7% vs 0% NCT05357755
sPGA 0/1
- HS-20118
- —Not reported
- icotrokinra
- —Trial running · NCT06295692
DLQI, change
- HS-20118
- —Not reported
- icotrokinra
- —Trial running · NCT06295692
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
HS-20118: no structured comparison results are available for Psoriasis.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. HS-20118: 0 of 4 rows · icotrokinra: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | icotrokinra |
|---|---|
| Dropout rate | 4.2%200 mga NCT06095115 · Phase 3 · monotherapy · Psoriasis · phase 3 show 17 more results—200 mg NCT06095115 · Phase 3 · monotherapy · Psoriasis · phase 3 —200 mg NCT06095115 · Phase 3 · monotherapy · Psoriasis · phase 3 —200 mg NCT06095115 · Phase 3 · monotherapy · Psoriasis · phase 3 —200 mg NCT06095115 · Phase 3 · monotherapy · Psoriasis · phase 3 9.5%100 mg BID NCT05223868 · Phase 2 4.7%100 mg QD NCT05223868 · Phase 2 7%50 mg QD NCT05223868 · Phase 2 2.4%25 mg BID NCT05223868 · Phase 2 16.3%25 mg QD NCT05223868 · Phase 2 7.9%100 mg BID NCT05364554 · Phase 2 · registry result, not featured evidence 17.5%100 mg QD NCT05364554 · Phase 2 · registry result, not featured evidence 17.1%100 mg QD NCT05364554 · Phase 2 · registry result, not featured evidence 15.4%50 mg QD NCT05364554 · Phase 2 · registry result, not featured evidence 25%25 mg BID NCT05364554 · Phase 2 · registry result, not featured evidence 22.9%25 mg QD NCT05364554 · Phase 2 · registry result, not featured evidence 5.9%50 mg QD NCT05357755 · Phase 2 · registry result, not featured evidence 29%10 mg QD NCT05357755 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 1.1%200 mga NCT06095115 · Phase 3 · monotherapy · Psoriasis · phase 3 show 17 more results—200 mg NCT06095115 · Phase 3 · monotherapy · Psoriasis · phase 3 —200 mg NCT06095115 · Phase 3 · monotherapy · Psoriasis · phase 3 —200 mg NCT06095115 · Phase 3 · monotherapy · Psoriasis · phase 3 —200 mg NCT06095115 · Phase 3 · monotherapy · Psoriasis · phase 3 —100 mg BID NCT05223868 · Phase 2 —100 mg QD NCT05223868 · Phase 2 —50 mg QD NCT05223868 · Phase 2 —25 mg BID NCT05223868 · Phase 2 —25 mg QD NCT05223868 · Phase 2 —100 mg BID NCT05364554 · Phase 2 · registry result, not featured evidence —100 mg QD NCT05364554 · Phase 2 · registry result, not featured evidence —100 mg QD NCT05364554 · Phase 2 · registry result, not featured evidence —50 mg QD NCT05364554 · Phase 2 · registry result, not featured evidence —25 mg BID NCT05364554 · Phase 2 · registry result, not featured evidence —25 mg QD NCT05364554 · Phase 2 · registry result, not featured evidence —50 mg QD NCT05357755 · Phase 2 · registry result, not featured evidence —10 mg QD NCT05357755 · Phase 2 · registry result, not featured evidence |
| Serious AEs | —200 mga NCT06095115 · Phase 3 · monotherapy · Psoriasis · phase 3 show 17 more results1.1%200 mg NCT06095115 · Phase 3 · monotherapy · Psoriasis · phase 3 1.3%200 mg NCT06095115 · Phase 3 · monotherapy · Psoriasis · phase 3 2.1%200 mg NCT06095115 · Phase 3 · monotherapy · Psoriasis · phase 3 1.8%200 mg NCT06095115 · Phase 3 · monotherapy · Psoriasis · phase 3 0%100 mg BID NCT05223868 · Phase 2 4.7%100 mg QD NCT05223868 · Phase 2 2.3%50 mg QD NCT05223868 · Phase 2 0%25 mg BID NCT05223868 · Phase 2 0%25 mg QD NCT05223868 · Phase 2 2.6%100 mg BID NCT05364554 · Phase 2 · registry result, not featured evidence 5%100 mg QD NCT05364554 · Phase 2 · registry result, not featured evidence 2.9%100 mg QD NCT05364554 · Phase 2 · registry result, not featured evidence 5.1%50 mg QD NCT05364554 · Phase 2 · registry result, not featured evidence 7.5%25 mg BID NCT05364554 · Phase 2 · registry result, not featured evidence 0%25 mg QD NCT05364554 · Phase 2 · registry result, not featured evidence 5.9%50 mg QD NCT05357755 · Phase 2 · registry result, not featured evidence 0%10 mg QD NCT05357755 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 200 mga nasopharyngitis 2.5% (placebo 6.6%) upper respiratory tract infection 1.4% (placebo 7%) NCT06095115 · Phase 3 · monotherapy · Psoriasis · phase 3 show 16 more results200 mg nasopharyngitis 6.8% (placebo 6.6%) upper respiratory tract infection 6.6% (placebo 7%) NCT06095115 · Phase 3 · monotherapy · Psoriasis · phase 3 200 mg nasopharyngitis 14.6% (placebo 6.6%) upper respiratory tract infection 8.3% (placebo 7%) NCT06095115 · Phase 3 · monotherapy · Psoriasis · phase 3 200 mg nasopharyngitis 12.5% (placebo 6.6%) upper respiratory tract infection 5.4% (placebo 7%) NCT06095115 · Phase 3 · monotherapy · Psoriasis · phase 3 100 mg BID covid-19 9.5% (placebo 11.6%) nasopharyngitis 4.8% (placebo 4.7%) upper respiratory tract infection 4.8% (placebo 2.3%) NCT05223868 · Phase 2 100 mg QD cough 7% (placebo 0%) headache 7% (placebo 2.3%) covid-19 4.7% (placebo 11.6%) NCT05223868 · Phase 2 50 mg QD nasopharyngitis 18.6% (placebo 4.7%) diarrhoea 9.3% (placebo 2.3%) covid-19 7% (placebo 11.6%) NCT05223868 · Phase 2 25 mg BID covid-19 19.5% (placebo 11.6%) nasopharyngitis 7.3% (placebo 4.7%) diarrhoea 4.9% (placebo 2.3%) NCT05223868 · Phase 2 25 mg QD covid-19 11.6% (placebo 11.6%) upper respiratory tract infection 7% (placebo 2.3%) diarrhoea 4.7% (placebo 2.3%) NCT05223868 · Phase 2 100 mg BID nasopharyngitis 13.2% upper respiratory tract infection 10.5% covid-19 7.9% NCT05364554 · Phase 2 · registry result, not featured evidence 100 mg QD nasopharyngitis 27.5% headache 7.5% arthralgia 5% NCT05364554 · Phase 2 · registry result, not featured evidence 100 mg QD nasopharyngitis 25.7% upper respiratory tract infection 11.4% alanine aminotransferase increased 5.7% NCT05364554 · Phase 2 · registry result, not featured evidence 50 mg QD nasopharyngitis 17.9% bronchitis 7.7% covid-19 7.7% NCT05364554 · Phase 2 · registry result, not featured evidence 25 mg BID nasopharyngitis 15% headache 7.5% influenza 7.5% NCT05364554 · Phase 2 · registry result, not featured evidence 25 mg QD upper respiratory tract infection 17.1% nasopharyngitis 8.6% headache 5.7% NCT05364554 · Phase 2 · registry result, not featured evidence 50 mg QD covid-19 8.8% (placebo 0%) back pain 5.9% (placebo 0%) headache 5.9% (placebo 0%) NCT05357755 · Phase 2 · registry result, not featured evidence 10 mg QD alanine aminotransferase increased 6.5% (placebo 0%) aspartate aminotransferase increased 6.5% (placebo 0%) blood glucose increased 6.5% (placebo 0%) NCT05357755 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 13 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
icotrokinra
show 1 more result
show 2 more results
show 2 more results
show 7 more results
show 7 more results
show 2 more results
show 8 more results
show 7 more results
show 7 more results
+ 16 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HS-20118's landscape · icotrokinra's landscape